Gregory Honeycutt, MD
Pulmonary Disease · Houston, TXNPI 1760628325
Payments from drug & device makers
Across 138 payments — averaging $43.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$4K
- GSK$617
- Insmed, Inc.$393
- AbbVie$239
- Grifols USA, LLC$193
- Genentech USA, Inc.$191
- plus $794 from 23 others
What the payments were for
- Food & beverage$2,61343%
- Education$3,43157%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 6 | $3,618 |
| GSK | 36 | $617 |
| Insmed, Inc. | 20 | $393 |
| AbbVie(2 entities) | 12 | $239 |
| Grifols USA, LLC | 8 | $193 |
| Genentech USA, Inc. | 13 | $191 |
| Boehringer Ingelheim | 5 | $88 |
| Merck | 5 | $73 |
| AstraZeneca | 4 | $70 |
| Philips North America LLC | 3 | $67 |
| Inspire Medical Systems, Inc. | 2 | $52 |
| Sunovion Pharmaceuticals Inc. | 4 | $40 |
| Pulmonx Corporation | 2 | $40 |
| Electromed, Inc. | 2 | $34 |
| Tactile Systems Technology Inc | 1 | $33 |
| Mallinckrodt Hospital Products Inc. | 1 | $32 |
| Regeneron Healthcare Solutions, Inc. | 1 | $30 |
| Johnson & Johnson | 2 | $27 |
| Actelion Pharmaceuticals US, Inc. | 1 | $26 |
| Edwards Lifesciences | 1 | $25 |
| Sanofi Pasteur Inc. | 1 | $25 |
| ZOLL Respicardia, Inc. | 1 | $22 |
| Shire North American Group Inc | 1 | $22 |
| Sanofi | 1 | $20 |
| Masimo Corporation | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Boston Scientific | 1 | $14 |
| Covis Pharma GmbH | 1 | $12 |
| Mylan Specialty L.p. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$3,506
How this compares
$6,045 in reported general payments places this provider in the 60th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 43 | $577,433 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 282 | $285,235 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 91 | $91,559 |
| NucalaMepolizumab | 13 | $62,666 |
| Dupixent PenDupilumab | 12 | $45,319 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 49 | $42,914 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 38 | $29,768 |
| SymbicortBudesonide/Formoterol Fumarate | 42 | $17,261 |
| XareltoRivaroxaban | 16 | $16,512 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $12,249 |
| Ipratropium Bromide | 210 | $11,231 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 225 | $9,776 |
| Levocetirizine Dihydrochloride | 326 | $7,913 |
| Montelukast Sodium | 459 | $7,882 |
| Fluticasone Propionate | 322 | $4,796 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat | $88 | $607,20081 claims |
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta | $617 | $403,063362 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Pulmicort Flexhaler | $70 | $112,270146 claims |
| Johnson & JohnsonXarelto | $27 | $16,51216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Houston
- Ivan RosasHouston$13.8M
- Nicola HananiaHouston$2.2M
- Sandeep SahayHouston$2.1M
- Zeenat SafdarHouston$1.7M
- Howard HuangHouston$1.3M
- Dileep PuppalaHouston$1.1M
- Sandeep GuptaHouston$1.1M
- Joseph VaronHouston$1.1M
- Bela PatelHouston$974K
- Roberto CasalHouston$865K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.